Intravenous immunoglobulin and multiple sclerosis

Anat Achiron*, Shmuel Miron

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Intravenous immunoglobulin (IVIg) has been used as an immunomodulatory therapy for the treatment of multiple sclerosis (MS). In the current review, we summarize the up-to-date data related to IVIg clinical trials in MS, and the suggested mechanisms of action by which IVIg modulates the relevant immunological pathways impaired in MS.

Original languageEnglish
Pages (from-to)247-254
Number of pages8
JournalClinical Reviews in Allergy and Immunology
Issue number3
StatePublished - Dec 2005


  • Autoimmunity
  • Immune system diseases
  • Intravenous immunoglobulins
  • Mechanisms
  • Multiple sclerosis


Dive into the research topics of 'Intravenous immunoglobulin and multiple sclerosis'. Together they form a unique fingerprint.

Cite this